UNIQURE INVESTIGATION: QURE Securities Investors Encouraged to Contact Kirby McInerney LLP About Their Rights
Kirby McInerney LLP announced it is investigating potential securities-law claims against uniQure N.V. (NASDAQ: QURE); no lawsuit has been filed. The investigation follows uniQure's September 29 disclosure that 48-month data for AMT-130 in Huntington's disease showed 44% slowing of disease progression, down from 75% at 36 months, on which basis the BLA had been submitted. QURE shares fell $14.60, or roughly 37.3%, from $39.11 to $24.51 on the disclosure.
Key figures
- New close
- 24.51
- Prior close
- 39.11
- Share price decline pct
- 37.3%
- Share price decline usd
- $14.60
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.